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Summary Cell growth survival studies have revealed that 7-OH methotrexate is two orders of magnitude less
cytotoxic to human melanoma and human acute lymphoblastic leukaemia (ALL) cells in vitro than
methotrexate. The influence of 7-OH methotrexate on methotrexate toxicity was investigated by studying cell
growth in the presence of methotrexate and its 7-OH metabolite and by studying [3H]-methotrexate movement
across the plasma membrane of isolated human cells. Transport was followed for net entry of the drug into
drug-free cells, net exit of drug into drug-free medium and for unidirectional exit fluxes with drug and/or
metabolite in the extracellular medium (exchange exit). Results indicate that 7-OH methotrexate (10-6M)
interacts with melanoma cells to reduce the initial cellular uptake rate of [3H]-methotrexate but that no such
interaction occurs with ALL cells. Efflux measurements revealed that a stimulatory effect of extracellular
methotrexate on [3H]-methotrexate exit was apparent and that extracellular 7-OH methotrexate had a less
stimulatory effect. Overall, loss of intracellular drug was greater from melanoma cells than from ALL cells.
The results suggest that the drug resistance encountered following high dose therapy may be due to reduced
cellular uptake and/or increased efflux of methotrexate from cells, both events being enhanced by 7-OH
methotrexate. In addition, there is an apparently endogenous resistance of the melanomas to methotrexate as
regards time of exposure to this agent which could also contribute to the lack of clinical response when
compared to ALL.
In a previous study it was shown that two factors
may contribute to the continued survival of tumour
cells in vivo from the effects of high-dose
methotrexate therapy with leucovorin rescue. These
two factors were: 1. The concentration of 7-OH
methotrexate in plasma which may be sufficient to
inhibit the further uptake of methotrexate. 2. The
rescue agent leucovorin which may salvage both
host tissue and viable tumour cells from the toxic
effects ofmethotrexate.
This study reports on the role that the 7-OH
metabolite of methotrexate may have in affording
protection to tumour cells against methotrexate. To
date this aspect of methotrexate therapy has
received limited attention (Lankelma et al., 1980)
and the major concern for this metabolite is for its
role in renal toxicity during high dose therapy
(Jacobs et al., 1976).
The effect of methotrexate on the toxicity to
human melanoma and human acute lymphoblastic
leukaemia (ALL) cells in the presence of 7-OH
methotrexate was investigated. A companson was
made of the melanoma cell lines ADLER, B8 and
BlO with the ALL cell line KM3, which was
reported to be methotrexate sensitive in vivo
(Schnieder et al., 1977). Transport of [3H]-
methotrexate across the plasma membrane of ALL
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and melanoma cells was also investigated for
comparison with the earlier results obtained using
the melanoma cell lines (Gaukroger et al., 1983).
Materials and methods
The cell lines used and cell culture techniques
employed were given previously (Gaukroger et al.,
1983). Radiolabelled material was purchased from
Amersham International plc., Amersham,
Buckinghamshire, UK.
Relative cell counts
The response of the cell lines to growth in the
presence of MTX and 7-OH MTX was compared
after 7 days incubation. Cell numbers in the culture
flasks were determined, following treatment with
EDTA solution, by counting on a Coulter Counter
model D with coincidence correction. The cell
numbers in the experimental flasks are expressed as
a percentage of the number of cells in the control
flasks. This value is referred to as relative cell count
RCC.
Measurement ofthe competition between 7-OH MTX
and MTXfor cellular influx andefflux
Details of the method used for entry of solute have
been given previously (Gaukroger et al., 1983) and
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only details of the efflux measurements will be
given here. For unidirectional measurement of
fluxes, simple integrated, rate-equation plots were
performed (Eilam & Stein, 1973).
Efflux of (3; 5; 7'-3H) MTX from cells and the
influence of MTX and 7-OH MTX on this process
was investigated. Cells were initially loaded with
[3H]-MTX by suspension in a solution of
radiolabelled methotrexate (2,uCiml-1) and the
concentration adjusted to 10-7M by addition of
unlabelled MTX. This was carried out by
suspending the cells in RPMI 1640 and incubating
at 37°C for 1h. Following the addition of
hydroxy[14C]methylinulin (0.2yCiml-1) (Sp. act.
0.91Cimg-') cells were separated from loading
medium by centrifugation at 150g for 5min.
Experiments were started by addition of RPMI
1640 efflux buffer (37°C) to the pre-warmed cell
pellet and resuspension of the cells achieved by
gentle agitation. Duplicate aliquots (200gl) of the
cell suspension were removed at various times (to
determine cell numbers) and cells separated from
medium by centrifugation through a mixture of
bromodecanes (Sp. gr. 1.05) Contamination of the
cell pellet with [14C]inulin was not detected and no
correction was therefore made for extracellular
[3H]-MTX. However, correction was required for
determination of the cellular [3H]-MTX content at
time zero and for the influx studies on the KM3
cell line. These have been described previously.
B8
Results
Effect ofmethotrexate and 7-OH methotrexate on
cell growth
Methotrexate Three profiles of the effect of
various concentrations of MTX on cell growth
(measured as relative cell number) are shown in
Figure 1 for the melanoma cell lines B8 and
ADLER, and for the ALL cell line KM3. The B8
and KM3 cell lines exhibited a transition from
survival (>20%) to toxicity to MTX at
10-9/10-8M whereas this occured at 10-8/10-7M
for the ADLER cell line.
7-OH methotrexate The same three cell lines as
above were exposed to various concentrations of 7-
OH MTX as indicated and dose response profiles
obtained which exhibited a survival/toxicity cut-off
point at 10-7/10-6M for KM3 and 10-6/10-5M
for B8 and ADLER (Figure 2).
Methotrexate and 7-OH methotrexate combined
The two melanoma cell lines B8 and ADLER were
grown in various concentrations of equimolar
mixtures of MTX and 7-OH MTX. When the
relative cell number was plotted against
concentration, toxicity profiles intermediate
between the two single agent profiles were obtained
(Figure 3) with greater survival of cells above the
ADLER KM3
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Figure 1 Response profiles for B8, ADLER (melanoma) and KM3 (ALL) cell lines treated with molar
concentrations of methotrexate.
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Figure 2 Response profiles for B8, ADLER (melanoma) and KM3 (ALL)
concentrations of 7-OH methotrexate.
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Figure 3 Response profiles for B8 and ADLER
melanoma cell lines treated with equimolar mixtures of
methotrexate and 7-OH methotrexate.
cut off points of 10-8/10-7M for the ADLER cell
line and 10-9/10-8M for the B8 cell line.
Effect oftime of exposure to methotrexate on cell
growth
Following different durations of exposure to MTX
and rescue with leucovorin, cell survival/growth
profiles were obtained by plotting relative cell
number against time of exposure to methotrexate.
(Figure 4). The melanoma cell lines showed less
cell lines treated with molar
sensitivity to 10-5M methotrexate even following
24h contact with this cytotoxic agent. Following
8 h exposure to MTX the ALL cell line KM3
showed a toxic response which was not reversible,
whereas for the three melanoma cell lines the
relative cell numbers were between 75% and 90%
of the control.
Competition of 7-OH methotrexatefor the uptake of
[3H]-methotrexate
Figure 5 shows the time course of the intracellular
accumulation of [3H]-Methotrexate (0.1 tM)
following incubation of the ALL cell line, KM3, in
the absence or presence of 7-OH methotrexate. The
effect of 1 iM 7-OH MTX on uptake of [3H]-MTX
by the KM3 cell line was minimal whereas the
effect of 100 MM 7-OH MTX was greater and
essentially the same for both melanoma and ALL
cell lines (Gaukroger et al., 1983). If the data for
the uptake of [3H]-MTX is plotted as a first order
reaction then a straight line relationship becomes
apparent for the initial uptake period (Figure 6).
This allows calculation of initial uptake rates of
[3H]-MTX for the ALL and melanoma (138 &
125dpmmin-1) in the absence of extracellular 7-
OH MTX. In the presence of this metabolite the
decrease in the rate of uptake is greater for the
melanoma (70dpmmin 1) than for the ALL
(128dpmmin -1).
100 -
Ir u
u
I _ I
AI ElD
D :~330 J.M. GAUKROGER & L. WILSON
1 U
c
cc
Time (h) of exposure to MTX
Figure4 MethotrexateexposuretimecourseforcellkillofB8(0),BIO(A),MEL57(E)andKM3(0).Following contact with 10-5M MTX, for the times indicated, cells were rescued by changing the culture medium to one containing leucovorin. Incubation was continued for a further 7days when cell numbers were determined and the results expressed as a percentage relative to cell numbers obtained in the absence of MTX.
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Figure 5 Time course of uptake of [3H]-MTX
(10-7M) into KM3 (ALL) cells in vitro. Cells were
incubated with a constant amount of [3-H]-labelled
drug and unlabelled 7-OH MTX added. (0) Control
(no 7-OH MTX), (0) 10-6M 7-OH MTX, (M) 10-4M 7-OH MTX.
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Figure 6 Integrated rate plot for [3H]-MTX entry
measurement in the absence [(O) B8 melanoma; (El) KM3, ALL] or presence [(0) B8, melanoma; (0) KM3, ALL] of 10-4M 7-OH MTX. St is the
intracellular radioactivity at time t and Soo is the
intracellular radioactivity at time infinity. Experimental conditions were those described in
Materials and methods.
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Effect ofmethotrexate and 7-OH methotrexate on
the efflux of[13H]-methotrexate
Figure 7 shows the time course for the loss of [3H]-
MTX from the cell line KM3 (ALL) during
incubation at 37°C with either MTX (10-6M) or 7-
OH MTX (10-6M) or in the absence of drug.
There was an initial rapid loss of intracellular [3H]-
MTX followed by a steady fall to virtually a
plateau by 30min from the start of efflux
measurements. In the presence of extracellular
methotrexate or 7-OH metabolite there was an
increase in the efflux of [3H]-MTX from all the cell
lines studied.
0
v-
x
0)
a
E
0.
'a
x
I
F-
0
x
LL
4000
2000
10 20
2). The detoxifying effect of the 7-OH metabolite
was illustrated by the results of experiments using
equimolar mixtures of methotrexate and 7-OH
methotrexate (Figure 3), when the effectiveness of
the parent molecule was reduced.
The present work shows that an ALL cell line,
which is responsive to high-dose methotrexate
therapy in vivo has a [3H]-MTX uptake profile
(Figure 5) similar to that of the melanoma cell lines
(Gaukroger et al., 1983), although the uninhibited
amount of [3H]-MTX taken up by the ALL cells
was less (Table I). An inhibitory effect on uptake of
[3H]-MTX by ALL cells was noted for the 7-OH
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Figure7 Timecoursesofeffluxof[3H]-MTXfromKM3cellsinvitro.Cells,loadedwith[3H]-MTXwereincubatedin theabsenceoflabelleddrugandunlabelled MTX or7-OHMTXadded.(0), nodrug(control),(A) 10-67-OHMTX and (El) 10 -M MTX.
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The data are plotted as a first order reaction in
Figures 8a, b and c. The effect of extracellular
solute on the efflux of [3H]-MTX is apparent,
although only the B8 cell line responds with a
much greater efflux of [3H]-MTX to extracellular
methotrexate. Table I shows that the two
melanoma cell lines retained less [3H]-MTX than
the ALL cell line. The amounts retained were
decreased in the presence of 7-OH methotrexate
and to a greater extent in the presence of
methotrexate.
Discussion
Dose response profiles for 7-OH methotrexate
revealed that it was less toxic to melanoma and
ALL cells than the parent molecule (Figures 1 and
c
metabolite only at high concentration (Figure 5) and from the first order plot of [3H]-MTX uptake (Figure 6) it is apparent that the effect of 10-4M 7-
OH MTX is greater on melanoma than ALL cells.
This would indicate that the pathway for entry into the cell is different for the ALL cell line, or the
affinity of substrates for carriers are different, although the intracellular binding sites of MTX and its 7-OH metabolites may well be the same. In high dose therapy, entry of methotrexate occurs by diffusion in addition to any mediated transport
across the cell membrane (Goldman, 1975) and it is
possible that melanoma cells are less permeable to
methotrexate by diffusion and that entry occurs
mainly via a mediated process that exhibits
saturation (Goldman et al., 1968; Gaukroger et al., 1983).
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a Time (min) We have shown that both methotrexate and its 7-
10 20 30 40 50 60 OH metabolite increase the efflux of [3H]-MTX from cells (Figure 7). The first order plots of these
data for KM3 cells and for the two melanoma cell
lines B8 and B1O (Figures 8a, b and c). reveal that
methotrexate has a greater effect than 7-OH methotrexate on the efflux process. However, it is
also apparent that for the melanoma cell lines, loss
of [3H]-MTX is more rapid and extensive than for
-0.5 the ALL cell line. As a result there is greater
retention of methotrexate within ALL cells than
b within melanoma cells, indicating a
biochemical/membrane ettect such that the etilux
rate reached a net zero position. Either this
happened because extracellular MTX was re-
entering the cell and/or because MTX was fixed in
the cell in a semi-permanent state. However, it is
unlikely that the loss of methotrexate from cells in
vivo occurs as rapidly because of the slow fall in
plasma methotrexate concentration (Fry et al.,
1983; Gaukroger et al., 1983) which will tend to
maintain intracellular methotrexate levels.
Since inhibition of dihydrofolate reductase is only
achieved when methotrexate is present in excess
amounts (White & Goldman, 1976) the
combination of reduced entry and enhanced efflux,
both leading to lower sustained levels of
methotrexate, could contribute to the clinical
resistance of melanoma. Although the dose-
response profiles to continuous contact in vitro are
virtually identical, a major difference between
melanoma and ALL is the time of exposure to
methotrexate required for a toxic response to
c become evident (Figure 4). The shorter time
10 20 30 40 50 60 required to inhibit KM3 cell division could be due
.~~~~~~~~~~~~~~~~~~4 . I_ v1 .- I 1 I 1 to nigner sustainea intracellular levels of
methotrexate, produced and maintained by a
mechanism such as formation of methotrexate
polyglutamates which are retained within the cell
(Fabre et al., 1983; Matherly et al., 1983) and
which in combination with a short cell cycle may
lead to exhaustion of reduced folate and rapid cell
death (Jacobs et al., 1975). Polyglutamates of MTX
or its 7-OH metabolite were not identified in
cultures of human melanoma cells incubated with
MTX (Gaukroger et al., 1983) but have been
identified in ALL cells (Fabre et al., 1983).
Figure 8 Integrated rate plot for [3H]-MTX exit
measurements from (a) KM3 (b) B8 and (c) B1O cells
in the absence (-) or presence of 10-6M 7-OH MTX
(C]) or 10-6 MTX (A). St is the intracellular
radioactivity remaining after time t and So is the
intracellular radioactivity at time zero. Experimental
conditions were those described in Materials and
methods.
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Table I Data of exit measurements for efflux of [3H]-MTX from melanoma and ALL
cell lines. The amounts of methotrexate remaining within the cells 60min from the start
of efflux measurements (time zero) are shown in the absence and presence of 10-6M
MTX or 7-OH MTX.
Cell Line B8 B1O KM3
Amount of MTX at time pg pg pg
zero (pg 5 x 10 cells) 57.3 69.6 46.1
Amount of MTX at 60 C 28.1 (49.1) 22.6 (32.4) 31.7 (68.9)
min (pg 5 x 10-5
cells) and as a % of 7-OH 25.2 (43.8) 16.9 (24.3) 28.1 (61.1)
the amount at time
zero. MTX 17.0 (32.1) 15.4 (22.1) 27.1 (58.9)
In conclusion, 7-OH MTX interferes with toxicity
of MTX to melanoma cells. MTX is rapidly lost
from melanoma cells (possibly due to the lack of
polyglutamate formation) when compared to an
ALL and less drug is retained within cells in the
presence of 7-OH MTX as a result of inhibited
entry and enhanced exit of methotrexate. It was
shown previously (Gaukroger et al., 1983) that 7-
OH MTX levels in plasma approached 10-5M
about 8 h from the start of an infusion and
exceeded MTX levels about 4/5h later. Unless cells
show irrevocable damage within this time scale it is
possible, for the reasons outlined above, that 7-OH
MTX salvages cells from MTX toxicity until rescue
by leucovorin occurs.
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